New Research on COVID-19 and the Insulin/IGF Pathway
Understanding the Mechanisms of SARS-CoV-2
Recent studies have consistently emerged regarding the effects of COVID-19 on the body, particularly how the SARS-CoV-2 virus interacts with biological pathways. A new investigation conducted by Osaka University in Japan has revealed that the virus disrupts the insulin/IGF pathway. This discovery may shed light on certain COVID-19 symptoms, such as diabetes and insulin resistance, which are related to energy metabolism.
The Role of the Insulin/IGF Pathway
The insulin/IGF pathway is essential for energy metabolism and the regulation of the cell life cycle. Insulin is a hormone that helps control blood sugar levels; when blood sugar rises, insulin is released, facilitating sugar absorption by body cells for metabolism. Disruption of this pathway can lead to insulin resistance, which is associated with several conditions, including diabetes, obesity, and hyperglycemia. If the insulin/IGF pathway is impaired, it can result in increased insulin resistance and related health issues.
SARS-CoV-2’s Impact on the Insulin/IGF Pathway
Researchers utilized existing datasets from previously infected COVID-19 patients to analyze gene expression. They specifically examined the transcriptome, focusing on genes that exhibited overexpression or underexpression in patients, live tissue models, and other laboratory settings. Through this analysis, it was found that SARS-CoV-2 led to an overexpression of IRF1, a protein that inhibits the insulin/IGF pathway. This mechanism may clarify the onset of insulin resistance and diabetes associated with COVID-19.
IRF1 Levels in Severe COVID-19 Cases
The study included whole blood transcriptomes from COVID-19 patients, comparing 46 critical care patients requiring ventilation with 23 non-critical care patients. Results indicated that IRF1 was significantly elevated in those with severe COVID-19 symptoms compared to those with milder cases. Additionally, gene expression related to the insulin/IGF pathway was notably downregulated in critical cases, suggesting a connection between elevated IRF1 levels and severe COVID-19.
IRF1 Expression and Risk Factors
Several risk factors for severe COVID-19, including age, obesity, male sex, and diabetes, were explored in relation to IRF1 expression. Findings showed increased IRF1 levels in the lung tissue of older patients, particularly in males. This suggests that higher concentrations of IRF1 may contribute to the increased severity of COVID-19 in older males. Further studies on obese and diabetic models in hamsters confirmed that these conditions elevate IRF1 expression in liver cells, supporting the hypothesis that obesity and diabetes are significant risk factors for severe COVID-19.
Potential Therapeutics: DHT and DEX
Both dihydrotestosterone (DHT) and dexamethasone (DEX), a common anti-inflammatory hormone, have shown promise in reducing IRF1 expression and enhancing the insulin/IGF pathway in samples infected with SARS-CoV-2. Since DHT levels tend to decline with age, this finding aligns with observations that younger individuals are less susceptible to severe COVID-19. While further research is necessary to assess the clinical applications of these therapeutic agents, the identified connection between SARS-CoV-2 infection and the insulin/IGF pathway may provide valuable insights for future COVID-19 treatments.
References
Shin, J. et al. (2022). SARS-CoV-2 infection impairs the insulin/IGF signaling pathway in the lung, liver, adipose tissue, and pancreatic cells via IRF1. Metabolism; 133: 155236.
Lee, Y.H. et al. (2005). Microarray profiling of isolated abdominal subcutaneous adipocytes from obese vs non-obese Pima indians: increased expression of inflammation-related genes. Diabetologia; 48: 1776-1783.
Photo by Miguel Á. Padriñán at Pexels.